Response to letter Re: COVID-19 vaccination before immune checkpoint inhibitor initiation and the overall survival of patients with advanced cancer: A cohort study
Authors:
- Pierre-Etienne HeudelPHPierre-Etienne Heudel
- Romain VarnierRVRomain Varnier
- Jean-Yves BlayJBJean-Yves Blay
- 1 September 2026
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 247
Abstract
No abstract availableFunding Information
- Institut National Du Cancer
- European Commission
This publication has 8 references indexed in Scilit:
- Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-Related SurvivalCancer Discovery, 2026
- Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in FranceeClinicalMedicine, 2026
- SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated With RadiotherapyJournal of Thoracic Oncology, 2026
- COVID-19 vaccination before immune checkpoint inhibitor initiation and the overall survival of patients with advanced cancer: A cohort studyEuropean Journal of Cancer, 2026
- Validation of “SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade” in an independent cohort of 4,407 patientsCancer Letters, 2026
- Time-related biases in observational studies : an illustration with COVID-19 vaccination during immune checkpoint inhibitor therapymedRxiv, 2025
- SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockadeNature, 2025
- Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patientsEuropean Journal of Cancer, 2022